Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity

被引：0
|
作者：
Phillips, A. L. [1 ]
Edwards, N. C. [2 ]
Locklear, J. C. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Hlth Serv Consulting Corp, Boxboro, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P839
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [31] Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Sormani, Maria P.
    Freedman, Mark S.
    Aldridge, Julie
    Marhardt, Kurt
    De Stefano, Nicola
    NEUROLOGY, 2018, 90
  • [32] Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a
    Pohl, D
    Rostasy, K
    Gärtner, J
    Hanefeld, F
    NEUROLOGY, 2005, 64 (05) : 888 - 890
  • [33] Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a
    Salter, A.
    Lancia, S.
    Cutter, G.
    Fox, R.
    Marrie, R. A.
    Avila, R.
    Vignos, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 187 - 187
  • [34] Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis
    Prosser, LA
    Kuntz, KM
    Bar-Or, A
    Weinstein, MC
    VALUE IN HEALTH, 2004, 7 (05) : 554 - 568
  • [35] Infections in alemtuzumab patients previously treated with subcutaneous interferon beta-1a
    Lycke, J.
    Cohen, J. A.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Compston, D. A. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 658 - 658
  • [36] AUtoimmunity PRofile in INterferon beta-1a treated multiple sclerosis patients. The AUPRIN Study: Comparison of 2 different dosages of subcutaneous interferon beta-1a
    Verdun, E
    Giordano, L
    Cucci, MA
    Ricci, A
    Barbero, P
    Pipieri, A
    Clerico, M
    Aimo, G
    Durelli, L
    NEUROLOGY, 2005, 64 (06) : A384 - A385
  • [37] Efficacy and tolerability of intramuscular interferon beta-la compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF
    Minagar, Alireza
    Murray, T. Jock
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (04) : 1049 - 1055
  • [38] SAFE AND EFFECTIVE USE OF THE SINGLE-USE INTRAMUSCULAR (IM) INTERFERON BETA-1A (IFNβ-1A) AUTOINJECTOR IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
    Phillips, J. T.
    Tuccillo, D.
    Liu, S.
    Curnow, K.
    Deykin, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 537 - 537
  • [39] Impact of the Presence of Gadolinium-Enhancing (Gd plus ) Lesions at Baseline on No Evidence of Disease Activity (NEDA) Status in Patients Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a): A Post-hoc Analysis of REFLEXION
    Freedman, Mark S.
    Comi, Giancarlo
    Coyle, Patricia K.
    Aldridge, Julie
    Marhardt, Kurt
    Kappos, Ludwig
    NEUROLOGY, 2018, 90
  • [40] Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis
    Guijarro, Cristina
    Benito-Leon, Julian
    Bermejo-Pareja, Felix
    NEUROLOGICAL SCIENCES, 2011, 32 (02) : 309 - 311
12345